Schade Kimberly N, Baranwal Aparna, Liang Christopher, Mirbolooki M Reza, Mukherjee Jogeshwar
Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697.
Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697.
Nucl Med Biol. 2015 Aug;42(8):691-4. doi: 10.1016/j.nucmedbio.2015.04.003. Epub 2015 Apr 16.
We have investigated β3-adrenoceptor agonist mediated brown adipose tissue (BAT) activation using (18)F-FDG PET/CT in Zucker lean (ZL) and obese (ZF) rats.
(18)F-FDG was injected into ZL and ZF rats pretreated with saline or agonist CL316,243 for scans. (18)F-FDG metabolic activity was computed as standard uptake values.
CL316,243 in ZL activated BAT up to 4-fold compared to saline, while ZF BAT was only up by 2 fold. The decreased activation was consistent with lower β3-adrenoceptor levels in ZF rats.
The genetically modified ZL and ZF rats may provide a useful rat model to evaluate the significance of β3-adrenoceptor agonist-induced BAT activation in obesity.
我们利用(18)F-FDG PET/CT在 Zucker 瘦素(ZL)大鼠和肥胖(ZF)大鼠中研究了β3-肾上腺素能受体激动剂介导的棕色脂肪组织(BAT)激活情况。
将(18)F-FDG 注入经生理盐水或激动剂 CL316,243 预处理的 ZL 和 ZF 大鼠体内进行扫描。(18)F-FDG 代谢活性以标准摄取值计算。
与生理盐水相比,ZL 大鼠体内的 CL316,243 使 BAT 激活高达 4 倍,而 ZF 大鼠的 BAT 仅增加了 2 倍。激活降低与 ZF 大鼠中较低的β3-肾上腺素能受体水平一致。
基因改造的 ZL 和 ZF 大鼠可能为评估β3-肾上腺素能受体激动剂诱导的 BAT 激活在肥胖中的意义提供有用的大鼠模型。